Arrowhead Pharmaceuticals (ARWR) has released an update.
Arrowhead Pharmaceuticals, Inc. is expanding its board by welcoming Dr. Hongbo Lu as an independent director starting April 1, 2024. With over two decades of healthcare investment expertise and board positions in more than 20 companies, Dr. Lu’s vast experience, including her roles at Vivo Capital and Lilly Asia Ventures, will be a significant asset to the company. Her comprehensive background in the industry is complemented by her education in Biological Engineering and an MBA. As part of her appointment, Dr. Lu will receive the company’s standard non-employee director compensation plus an additional equity grant.
For further insights into ARWR stock, check out TipRanks’ Stock Analysis page.
